Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors

Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin are FDA-approved for managing adult patients with type 2 diabetes mellitus (DM) to improve blood sugar control adjunct to diet and exercise. All four agents are sodium-glucose transport protein 2 (SGLT2) inhibitors acting on the SGLT-2 proteins expressed in the renal proximal convoluted tubules to reduce the reabsorption of filtered glucose, decrease the renal threshold for glucose (RTG), and promote urinary glucose excretion. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to interprofessional team members in managing adult patients with type 2 diabetes mellitus (DM) to improve glycemic control and reduce cardiovascular and renal complications.